- Home
- OCUP vs PLBY Comparison
OCUP vs PLBY Comparison
Compare OCUP & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUP
- PLBY
- Stock Information
- Founded
- OCUP 2018
- PLBY 1953
- Country
- OCUP United States
- PLBY United States
- Employees
- OCUP N/A
- PLBY N/A
- Industry
- OCUP Biotechnology: Pharmaceutical Preparations
- PLBY Recreational Games/Products/Toys
- Sector
- OCUP Health Care
- PLBY Consumer Discretionary
- Exchange
- OCUP Nasdaq
- PLBY Nasdaq
- Market Cap
- OCUP 53.1M
- PLBY 53.2M
- IPO Year
- OCUP N/A
- PLBY N/A
- Fundamental
- Price
- OCUP $1.29
- PLBY $0.68
- Analyst Decision
- OCUP Strong Buy
- PLBY Buy
- Analyst Count
- OCUP 3
- PLBY 2
- Target Price
- OCUP $18.67
- PLBY $2.35
- AVG Volume (30 Days)
- OCUP 85.0K
- PLBY 245.9K
- Earning Date
- OCUP 11-11-2024
- PLBY 11-07-2024
- Dividend Yield
- OCUP N/A
- PLBY N/A
- EPS Growth
- OCUP N/A
- PLBY N/A
- EPS
- OCUP N/A
- PLBY N/A
- Revenue
- OCUP $16,449,000.00
- PLBY $125,850,000.00
- Revenue This Year
- OCUP N/A
- PLBY N/A
- Revenue Next Year
- OCUP $258.69
- PLBY N/A
- P/E Ratio
- OCUP N/A
- PLBY N/A
- Revenue Growth
- OCUP N/A
- PLBY N/A
- 52 Week Low
- OCUP $1.15
- PLBY $0.43
- 52 Week High
- OCUP $3.53
- PLBY $1.55
- Technical
- Relative Strength Index (RSI)
- OCUP 45.88
- PLBY 54.98
- Support Level
- OCUP $1.25
- PLBY $0.72
- Resistance Level
- OCUP $1.33
- PLBY $0.77
- Average True Range (ATR)
- OCUP 0.08
- PLBY 0.05
- MACD
- OCUP 0.01
- PLBY 0.00
- Stochastic Oscillator
- OCUP 16.67
- PLBY 32.18
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.